Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial

Swaminathan P. Iyer, Shaker Dakhil, Michi M. Shinohara, Jasmine Zain, Mark Acosta, Francine Foss

Blood Neoplasia (2025) 2 (1): 100055.

https://doi.org/10.1016/j.bneo.2024.100055

Published: 2025

Journal Articles

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

Max J. Gordon, Sigrid Dubois, Milos D. Miljkovic, Samuel Ng, Bonita Bryant, Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, Kevin Conlon, Thomas Waldmann, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski

Blood Neoplasia (2025) 2 (1): 100054.

https://doi.org/10.1016/j.bneo.2024.100054

Published: 2025

Journal Articles

Cerebrospinal fluid attenuates the efficacy of methotrexate against acute lymphoblastic leukemia cells

Jongseok Kang, Jason Ostergaard, Xiaohong Wang, Peter M. Gordon

Blood Neoplasia (2025) 2 (1): 100057.

https://doi.org/10.1016/j.bneo.2024.100057

Published: 2025

Includes: Supplemental data

Journal Articles

JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study

Yu Uemura, Masahide Yamamoto, Masataka Ishimura, Hirokazu Kanegane, Akihisa Sawada, Akihiro Hirakawa, Ken-Ichi Imadome, Mayumi Yoshimori, Masashi Nagata, Kouhei Yamamoto, Norio Shimizu, Ryuji Koike, Ayako Arai

Blood Neoplasia (2025) 2 (1): 100053.

https://doi.org/10.1016/j.bneo.2024.100053

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Matthew S. Davids, Jacob Ambrose, Enrico de Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z. H. Farooqui, Shravanthi R. Gandra, Christina M. Zettler, Laura L. Fernandes, Ching Kun Wang, Mazyar Shadman

Blood Neoplasia (2025) 2 (1): 100047.

https://doi.org/10.1016/j.bneo.2024.100047

Published: 2025

Includes: Supplemental data

Journal Articles

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Naveen Pemmaraju, Tim C.P. Somervaille, Francesca Palandri, Claire Harrison, Rami S. Komrokji, Andrew Perkins, Rosa M. Ayala Diaz, David Lavie, Akihiro Tomita, Yang Feng, Qin Qin, Jason Harb, Akshanth R. Polepally, Jalaja Potluri, Jacqueline S. Garcia

Blood Neoplasia (2025) 2 (1): 100056.

https://doi.org/10.1016/j.bneo.2024.100056

Published: 2025

Includes: Supplemental data

Journal Articles

Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma

Julia Erin Wiedmeier-Nutor, Michael A. Golafshar, Katie L. Kunze, Edward D. Esplin, Robert L. Nussbaum, Erik Jessen, Brandie Heald, A. Keith Stewart, N. Jewel Samadder, P. Leif Bergsagel, Rafael Fonseca

Blood Neoplasia (2025) 2 (1): 100045.

https://doi.org/10.1016/j.bneo.2024.100045

Published: 2025

Includes: Supplemental data

Journal Articles

Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol

David T. Yeung, Laura N. Eadie, Jacqueline Rehn, Susan L. Heatley, Barbara J. McClure, Elyse C. Page, Caitlin E. Schutz, Michael P. Osborn, Toby Trahair, Rosemary Sutton, Michelle J. Henderson, John Kwan, Sally Mapp, Luciano Dalla-Pozza, Kenneth Bradstock, Matthew Greenwood, Deborah L. White

Blood Neoplasia (2025) 2 (1): 100041.

https://doi.org/10.1016/j.bneo.2024.100041

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

Hiroki Kobayashi, Ryota Chijimatsu, Yusuke Naoi, Yoshihiro Otani, Ryo Mizuta, Kentaro Fujii, Joji Ishida, Hiroyuki Murakami, Hideki Ujiie, Kazuhiro Ikeuchi, Tomohiro Urata, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Nobuharu Fujii, Ken-ichi Matsuoka, Yasuharu Sato, Yoshinobu Maeda, Daisuke Ennishi

Blood Neoplasia (2025) 2 (1): 100058.

https://doi.org/10.1016/j.bneo.2024.100058

Published: 2025

Includes: Supplemental data

Journal Articles

New leads to enhance Tagraxofusp efficacy in pDC-AML

Morgane Boichut, Margaux Poussard, Xavier Roussel, Imane Belakri, Sabeha Biichle, Maxime Fredon, Florian Renosi, Romain Boidot, Olivier Adotevi, Christopher Brooks, Francine Garnache-Ottou, Fanny Angelot Delettre

Blood Neoplasia 100066.

https://doi.org/10.1016/j.bneo.2025.100066

Published: 2025

Includes: Supplemental data

Journal Articles

Real-World Safety Profile of therapy with Ibrutinib or Acalabrutinib in patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Ramsay Hafer, Francesco Iadevaia, Thomas Z. Rohan, Teresa Duong, Maria Poluch, Gina Keiffer, Michael Li, Andres Ferber, Luca Laurenti, Alan S Khoo, Pierluigi Porcu

Blood Neoplasia 100064.

https://doi.org/10.1016/j.bneo.2024.100064

Published: 2024

Includes: Supplemental data

Journal Articles

Outcomes of Follicular Lymphoma with Leukemic Phase in the Modern Era: Results from a Large Multicenter Study

Blood Neoplasia 100063.

https://doi.org/10.1016/j.bneo.2024.100063

Published: 2024

Includes: Supplemental data

Journal Articles

Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma

Bei Wang, Benjamin A. Derman, Madina Sukhanova, Daniel Appelbaum, John Cursio, Wei Zhang, Andrzej Jakubowiak, Brian C.-H. Chiu

Blood Neoplasia 100065.

https://doi.org/10.1016/j.bneo.2024.100065

Published: 2024

Journal Articles

Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm

Zhuoer Xie, Najla Al Ali, Ling Zhang, Peter Papenhausen, Virginia Olivia Volpe, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Alison Walker, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood Neoplasia 100062.

https://doi.org/10.1016/j.bneo.2024.100062

Published: 2024

Includes: Supplemental data

Journal Articles

Safety Landscape of Bispecific Antibody Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis

Rodrigo Fonseca, Alex J. Liu, Blake T. Langlais, Diana Almader-Douglas, Holenarasipur R. Vikram, Talal Hilal

Blood Neoplasia 100061.

https://doi.org/10.1016/j.bneo.2024.100061

Published: 2024

Includes: Supplemental data

Journal Articles

Loss of p53 Impairs Death Receptor Expression and Confers Resistance to CD19 CAR T Cell Therapy in BCP-ALL

Willem P.J. Cox, Noel M.M. Dautzenberg, Linde Dekker, Tesa Klenovsek, Annelisa M. Cornel, Marliek van Hoesel, Dorette S. van Ingen Schenau, Reno S. Bladergroen, Roland P. Kuiper, Laurens T. van der Meer, Friso G. Calkoen, Stefan Nierkens, Frank N. van Leeuwen

Blood Neoplasia 100060.

https://doi.org/10.1016/j.bneo.2024.100060

Published: 2024

Journal Articles

Aberrant Heterochromatin Silences Immune Response Genes in Chronic Lymphocytic Leukemia

Olivia M. Depies, Qianqian Guo, Yuan Gao, Sutapa Sinha, Zhenqing Ye, Weiguo Han, Kari G. Rabe, Mingma S. Hoel, Heather C. Darby, Chuanhe Yu, Esteban Braggio, Sameer A. Parikh, Susan L. Slager, Neil E. Kay, Zhiquan Wang

Blood Neoplasia 100059.

https://doi.org/10.1016/j.bneo.2024.100059

Published: 2024

Includes: Supplemental data

Journal Articles

Development and characterization of a low-affinity humanized CD19 chimeric antigen receptor for B-cell malignancies

Lawrence A. Stern, Vibhuti Vyas, Laura Lim, Christian Huynh, Ryan Urak, Ruby Espinosa, Zhiqiang Wang, Michalina Silva Thiel, John C. Williams, Stephen J. Forman, Christine E. Brown, Xiuli Wang

Blood Neoplasia (2024) 1 (4): 100048.

https://doi.org/10.1016/j.bneo.2024.100048

Published: 2024

Includes: Supplemental data

Journal Articles

Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma

Blood Neoplasia (2024) 1 (4): 100049.

https://doi.org/10.1016/j.bneo.2024.100049

Published: 2024

Includes: Supplemental data

Journal Articles

Deciphering MARCH5’s impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling

Hamed Bashiri, Ahad Khalilnezhad, Haruhito Totani, Joe Yeong, Tae-Hoon Chung, Felicia Wee, Yuezhen Xue, Zhen Wei Neo, Li Yen Chong, Wee Joo Chng, Atsushi Watanabe, Siok-Bian Ng, The Phyu, Toshio Suda

Blood Neoplasia (2024) 1 (4): 100046.

https://doi.org/10.1016/j.bneo.2024.100046

Published: 2024

Includes: Supplemental data

NARROW

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

Cerebrospinal fluid attenuates the efficacy of methotrexate against acute lymphoblastic leukemia cells

JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma

Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

New leads to enhance Tagraxofusp efficacy in pDC-AML

Real-World Safety Profile of therapy with Ibrutinib or Acalabrutinib in patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Outcomes of Follicular Lymphoma with Leukemic Phase in the Modern Era: Results from a Large Multicenter Study

Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma

Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm

Safety Landscape of Bispecific Antibody Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis

Loss of p53 Impairs Death Receptor Expression and Confers Resistance to CD19 CAR T Cell Therapy in BCP-ALL

Aberrant Heterochromatin Silences Immune Response Genes in Chronic Lymphocytic Leukemia

Development and characterization of a low-affinity humanized CD19 chimeric antigen receptor for B-cell malignancies

Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma

Deciphering MARCH5’s impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only